ArrePath, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ArrePath, Inc. - overview
Location
-, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded by its Chairman Zemer Gitai, ArrePath operates as an anti-infective drug discovery company. In June 2025, ArrePath, Inc. raised an undisclosed amount of venture funding led by new investor Boehringer Ingelheim Venture, with participation from another new investor AB Magnitude Ventures Group. Returning investors Insight Partners, Innospark Ventures, and Nor'easter Ventures also participated in the round.
The company provides an advanced machine learning (ML) and imaging-based drug discovery platform to identify new classes of antibiotics. It also provides drug discovery, microbiology, microscopy, and data science to develop life-saving anti-infectives. It offers phenotypic profiling and bacterial autopsies, artificial intelligence/machine learning-enabled drug design, multidimensional phenotypic screening, and proteomics. The company plans to utilize the June 2025 funding to harness innovative technologies and methodologies to speed up delivering advanced solutions to market.
Current Investors
Insight Partners, Boehringer Ingelheim Venture, Innospark Ventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Healthcare, Pharmaceutical Research & Development
Website
www.arrepath.com
Verticals
Artificial Intelligence
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.